| 23.37 1 (4.47%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.05 | 1-year : | 32.76 |
| Resists | First : | 24.02 | Second : | 28.05 |
| Pivot price | 20.81 |
|||
| Supports | First : | 18.13 | Second : | 14.5 |
| MAs | MA(5) : | 22.93 |
MA(20) : | 19.68 |
| MA(100) : | 16.97 |
MA(250) : | 19.55  |
|
| MACD | MACD : | 1.7 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 83.2 |
D(3) : | 85 |
| RSI | RSI(14): 68.1 |
|||
| 52-week | High : | 40.25 | Low : | 10.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SYRE ] has closed below upper band by 23.5%. Bollinger Bands are 167.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 23.61 - 23.7 | 23.7 - 23.81 |
| Low: | 22.11 - 22.2 | 22.2 - 22.31 |
| Close: | 23.19 - 23.35 | 23.35 - 23.53 |
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Fri, 24 Oct 2025
Spyre Therapeutics Presents Promising Phase 1 Data for SPY072 at ACR Convergence Congress - Quiver Quantitative
Fri, 24 Oct 2025
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 - The Manila Times
Fri, 24 Oct 2025
Spyre (NASDAQ: SYRE) shows SPY072 Phase 1 PK for quarterly/twice‑yearly dosing at ACR - Stock Titan
Fri, 24 Oct 2025
Spyre Therapeutics (SYRE) Investor Outlook: Unpacking A Potential 136% Upside - DirectorsTalk Interviews
Thu, 23 Oct 2025
Fairmount Funds Management LLC Increases Stake in Spyre Therapeutics Inc - GuruFocus
Mon, 20 Oct 2025
First Week of June 2026 Options Trading For Spyre Therapeutics (SYRE) - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 8.6 (%) |
| Held by Institutions | 106.9 (%) |
| Shares Short | 14,460 (K) |
| Shares Short P.Month | 14,090 (K) |
| EPS | -2.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.5 % |
| Return on Equity (ttm) | -49.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.94 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -154 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -9.24 |
| PEG Ratio | 0 |
| Price to Book value | 4.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|